AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results VALENCIA, Calif., USA

AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results

VALENCIA, Calif., USA, June 15, 2021, and MELBOURNE, Australia, June 16, 2021 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX:

AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple

unmet needs, today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021.

For the fiscal quarter ending June 30,

2021, AVITA Medical has to date realized total revenue in excess of its fiscal fourth quarter guidance range of $8.2 million to $8.6 million. Based on the strength of both RECELL

commercial revenue and BARDA related revenue, the Company is raising fiscal Q4 guidance to be in the range of $9.5 - $9.7 million, consisting of $6.0 - $6.2 million of RECELL

commercial revenue and $3.5 million of RECELL revenue associated with BARDA, the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority

within the Office of the Assistance Secretary for Preparedness and Response. RECELL commercial revenue as revised in the guidance reflects a 55% to 60% increase over the prior year period and

30% to 34% increase over the third quarter of 2021.

As people begin to return to normal activities after the confines of the COVID-19 pandemic, we

have seen an increase in burn accidents requiring treatment with the RECELL System in burn centers across the country, said Dr. Mike Perry, AVITA Medical s Chief Executive

The Company expects to announce fourth quarter financial and operating results on August 25, 2021. More details about the upcoming earnings

announcement, including the time and webcast details, will be provided at a later date.

The preliminary unaudited revenue results described in this press

release are estimates only and subject to revision until we report our Q4 2021 financial results in our Annual Report on Form 10-K.

For more information about the RECELL System, please visit https://recellsystem.com/.

ABOUT AVITA MEDICAL, INC.

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics

indications. AVITA Medical s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient s own skin. The medical devices work by preparing a

RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension

is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical s first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of

AVITA Medical Inc, 28159 Avenue

Stanford, Valencia, CA 91355

acute thermal burns. The RECELL System is used to prepare Spray-On Skin Cells using a small

amount of a patient s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts

depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant

advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE -

RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings,

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of

applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as

anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target,

project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to,

statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic,

operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause

actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our

products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the

effects of industry, economic or political conditions outside of the company s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly

available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

AVITA Medical Inc, 28159 Avenue

Stanford, Valencia, CA 91355

AVITA Medical Inc, 28159 Avenue

Stanford, Valencia, CA 91355